FDA to review Novartis diabetes drug
31st Mar 2006, 14:50 GMT
Swiss drugmaker Novartis has had its application for Galvus, its oral type 2 diabetes treatment, accepted for review by the FDA.
FDA to review Novartis diabetes drug related news:
- Novartis to Get FDA Galvus Review — Operations-Related News from StratCenter.com
- FDA to review Galvus, oral treatment for Type 2 diabetes — The Diabetes Blog
- FDA prüft Novartis-Zulassungsantrag für Galvus — Finanztreff.de / TOPTHEMEN
- Diabetes reversed in mice, FDA approves human trial — Pharmaceutical Business Review Latest News
- New drug application for Galvus, an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA — Nephrology/ Dialysis News from StratCenter.com
- New drug application for Galvus(R), an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA — PR Newswire: All Releases
- Novartis acquires Idenix hepatitis drug — Pharmaceutical Business Review Latest News
- New drug application for Galvus®, an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA — WebWire - Recent Headlines
- Dual Blockade of Renin-Angiotensin System in Diabetic Nephropathy: Review of Literature and Local Experience — Medscape Headlines
- Novartis-Chiron deadline approaches — Operations-Related News from StratCenter.com
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol